

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 10, 2022

**Century Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**001-40498**  
(Commission File Number)

**84-2040295**  
(I.R.S. Employer  
Identification No.)

**3675 Market Street**  
**Philadelphia, Pennsylvania**  
(Address of principal executive offices)

**19104**  
(Zip Code)

Registrant's telephone number, including area code: **(267) 817-5790**

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of Each Class</b>	<b>Trading Symbol</b>	<b>Name of Exchange on Which Registered</b>
Common Stock, par value \$0.0001 per share	IPSC	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01**            **Other Events**

On May 10, 2022, Century Therapeutics, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

**Item 9.01**            **Financial Statements and Exhibits**

(d) Exhibits

<b>Exhibit No.</b>	<b>Document</b>
<a href="#">99.1</a>	<a href="#">Investor Presentation of Century Therapeutics, Inc., dated May 10, 2022</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CENTURY THERAPEUTICS, INC.**

By: /s/ Osvaldo Flores, Ph.D.  
Name: Osvaldo Flores, Ph.D.  
Title: President and Chief Executive Officer

---

Date: May 10, 2022

---



# BofA SECURITIES 2022 HEALTHCARE CONFERENCE

May 10, 2022



# FORWARD-LOOKING STATEMENTS


---

This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements assumed future results of operations, business strategies, research and development plans, regulatory activities, market opportunity, competitive position and potential growth forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements such as "may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements on current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some are outside our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our ability to maintain or enhance our collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings; the timing of final regulatory approval of our product candidates; the impact of the COVID-19 pandemic on our business and operations, supply chain and labor force; the performance of third parties with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the "Risk Factors" section of our most recent filings with the Securities and Exchange Commission at [www.sec.gov](http://www.sec.gov). You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may or may not occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risks may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not intend to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.






# Future Vision



# CNTY-101: NEXT GENERATION CD19 TARGETED PRODUCT

## HIGHLY DIFFERENTIATED PROFILE

### Allo-Evasion™ edits



### CNTY-101


First cell product candidate with 6 gene edits introduced with CRISPR-HDR



## ELIPSE-1: PHASE 1 STUDY GOALS


- Dose escalation with multiple dose: lymphodepletion conditioning regimen
- IND submission on track for mid-advance CNTY-101 into Phase 1 clinical trial

### Clinically meaningful and platform validating data from ELIPSE-1 Schedule B



\* Subject to FDA approval

# COMMON PROGENITOR ENABLES EFFICIENT PIPELINE EXPANSION



## **iNK 3.0 common progenitor platform incorporates multiple features:**

- Additional Allo-Evasion edits
- Additional innate killing potential
- Additional anti-cancer targeting option
- Cytokine support



# PIPELINE

Product candidate pipeline across cell types and targets in solid and hematologic malignancies

Product	iPSC Platform	Targets	Indications	Expected IND Submission	Discovery	Preclinical	Clinical
CNTY-101	iNK	CD19	B-Cell Malignancies	Mid 2022			
CNTY-103	iNK	CD133 + EGFR	Glioblastoma	2023			
CNTY-102	iT	CD19 + CD79b	B-Cell Malignancies	2024			
CNTY-104	iNK/iT	Multi-specific	Acute Myeloid Leukemia	2024			
CNTY-106	iNK/iT	Multi-specific	Multiple Myeloma	2024			
Discovery Research Programs							
	iNK/iT	TBD	Solid Tumors	TBD			
	iNK/iT	TBD	Hematological Malignancies	TBD			



Solid Tumors Hematologic Tumors

# CENTURY THERAPEUTICS' UNIQUE INVESTMENT OPPORTUNITY

---

We are developing a portfolio of potentially best-in-class, differentiated allogeneic cell therapies that deliver durable responses

We are leveraging our iNK and  $\delta\gamma$  iT cell platforms to tackle tumors with unmet medical need

Our comprehensive iPSC-based platform is in place, allowing for rapid iteration

We are well capitalized with platform synergies and operational excellence to advance our portfolio and pipeline in 2022



A microscopic view of cells, likely cancer cells, rendered in a blue and red color scheme. The cells are interconnected by a network of fine, blue, fibrous structures. A large, central cell is highlighted in a vibrant red and orange, contrasting with the surrounding blue cells. The text "THANK YOU" is overlaid in white, bold, sans-serif font, centered horizontally and slightly above the middle vertically. A thin, horizontal teal line is positioned directly beneath the text.

**THANK YOU**

